Conference Call and Webcast to Follow at 5 p.m. Eastern

HOUSTON--(BUSINESS WIRE)--Mar. 4, 2015-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, will report fourth quarter and year-end 2014 financial results after the close of U.S. financial markets on Wednesday, March 11, 2015. Bellicum management will host a webcast and conference call at 5:00 p.m. Eastern that day to discuss the financial results and provide a business update.

To access the call, participants should dial (855) 779-9069 (U.S. domestic) and (631) 485-4863 (international) at least 10 minutes prior to the start of the call, using passcode 253830. The event will be webcast live and can also be accessed in the Investor and Media section of bellicum.com. An archived version of the webcast will also be available for replay in the Investor and Media section of our website for at least two weeks following the call.

About Bellicum Pharmaceuticals

Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company is using its proprietary Chemical Induction of Dimerization, or CID, technology platform to engineer and control components of the immune system in real time. The Company is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation, or HSCT, CAR T cell therapy, and dendritic cell vaccines.

Source: Bellicum Pharmaceuticals, Inc.

Investors:
Bellicum Pharmaceuticals, Inc.
Alan Musso, 832-384-1116
Chief Financial Officer
amusso@bellicum.com
or
Media:
Brad Miles, 646-513-3125
bmiles@bmccommunications.com